[Experiences with niflumic acid in inflammatory glomerulopathies]

Area of Science:

• Nephrology
• Pharmacology

Context:

• Glomerulonephritis is a significant cause of kidney disease characterized by proteinuria.
• The nephrotic syndrome requires effective therapeutic interventions to manage proteinuria and improve patient outcomes.

Purpose:

• To evaluate the efficacy of niflumic acid in treating patients with glomerulonephritis and proteinuria.
• To assess the impact of niflumic acid on kidney function and protein metabolism in these patients.

Summary:

• Thirty patients with glomerulonephritis and proteinuria received 750 mg/day of niflumic acid for an average of 4 months.
• Proteinuria decreased in 73% of patients; kidney function remained stable or worsened only in pre-compromised kidneys.
• Secretion of fibrinogen degradation products decreased in 70% of cases with initially elevated levels; effects were reversible upon drug cessation.

Impact:

• Niflumic acid demonstrates effectiveness in managing the nephrotic syndrome by improving protein metabolism.
• The drug's positive effects on protein metabolism suggest a potential to influence the overall prognosis of glomerulonephritis.
• Niflumic acid offers a treatment option with a potentially lower complication rate due to improved protein metabolism.